SCHEMBL2224753

SCHEMBL2224753

COc1ccc(O)c2ncccc12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 6/20 0.62
NPC1 O15118 6/20 0.62
KMT2A Q03164 5/20 0.62
MEN1 O00255 4/20 0.62
NSD2 O96028 1/20 0.62
CASP6 P55212 1/20 0.62
HTT P42858 6/20 0.61
SLC6A2 P23975 1/20 0.61
KDM4E B2RXH2 12/20 0.60
MAPT P10636 6/20 0.60
SMN1; SMN2 Q16637 4/20 0.60
TDP1 Q9NUW8 3/20 0.60
MAPK1 P28482 2/20 0.60
MMP14 P50281 1/20 0.60
RAB9A P51151 7/20 0.59
NPSR1 Q6W5P4 4/20 0.59
ALOX12 P18054 2/20 0.59
L3MBTL1 Q9Y468 5/20 0.56
LMNA P02545 3/20 0.56
MPI P34949 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1714045 0.86 KDM4E (0.54) HSP90AA1NPC1KMT2AMEN1NSD2
SCHEMBL9186410 0.86 KMT2A (0.55) HSP90AA1NPC1KMT2AMEN1NSD2
SCHEMBL1506959 0.85 HTR1A (0.53) HSP90AA1NPC1KMT2AMEN1NSD2
SCHEMBL4294109 0.84 KDM4E (0.53) HSP90AA1NPC1KMT2AMEN1NSD2
SCHEMBL6118557 0.82 KDM4E (0.59) HSP90AA1NPC1KMT2AMEN1CASP6
SCHEMBL13036181 0.80 KMT2A (0.50) HSP90AA1NPC1KMT2AMEN1NSD2
SCHEMBL637660 0.79 HTT (0.51) HSP90AA1NPC1KMT2AMEN1NSD2
SCHEMBL12566073 0.79 NSD2 (0.54) HSP90AA1NPC1KMT2AMEN1NSD2
SCHEMBL1132599 0.79 G6PD (0.54) HSP90AA1NPC1NSD2CASP6HTT
SCHEMBL625749 0.79 NSD2 (0.62) HSP90AA1NPC1KMT2AMEN1NSD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118243829-A Method for detecting effective components of montmorillonite medicament for treating diarrhea 南通大学附属医院 2024-06-25 CN claimed
CN-118243829-B Method for detecting effective components of montmorillonite medicament for treating diarrhea 南通大学附属医院 2024-08-30 CN disclosed
CN-118243829-A Method for detecting effective components of montmorillonite medicament for treating diarrhea 南通大学附属医院 2024-06-25 CN disclosed
CN-118243829-A Method for detecting effective components of montmorillonite medicament for treating diarrhea 南通大学附属医院 2024-06-25 CN disclosed
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression SIERRA SCIENCES, INC. (US) 2023-07-18 US disclosed
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression SIERRA SCIENCES, INC. (US) 2023-07-18 US disclosed
US-20210363008-A1 PROCESS FOR PREPARING A STABILIZED AQUEOUS HYDROGEN PEROXIDE SOLUTION EVONIK CORPORATION (US) 2021-11-25 US disclosed
US-20210307332-A1 POLYMER-STABILIZED AQUEOUS HYDROGEN PEROXIDE SOLUTIONS AND ASSOCIATED METHODS EVONIK CORPORATION (US) 2021-10-07 US disclosed
EP-3830027-A1 POLYMER-STABILIZED AQUEOUS HYDROGEN PEROXIDE SOLUTIONS AND ASSOCIATED METHODS Evonik Corporation (US) 2021-06-09 EP disclosed
EP-3830026-A1 PROCESS FOR PREPARING A STABILIZED AQUEOUS HYDROGEN PEROXIDE SOLUTION Evonik Corporation (US) 2021-06-09 EP disclosed
US-7169237-B2 Mixture of peroxide with stannates, phosphonates and pyrophosphates for cleaning surfaces ARKEMA INC. (US) 2007-01-30 US disclosed
US-7169743-B2 Stabilized thickened hydrogen peroxide containing compositions with a mixture of stabilizers ARKEMA INC. (US) 2007-01-30 US disclosed
US-7045493-B2 Stabilized thickened hydrogen peroxide containing compositions ARKEMA INC. (US) 2006-05-16 US disclosed
US-20060063695-A1 Stabilized thickened hydrogen peroxide containing compositions WANG XUE 2006-03-23 US disclosed
WO-2006016990-A2 STABILIZED THICKENED HYDROGEN PEROXIDE CONTAINING COMPOSITIONS ARKEMA INC. (US) 2006-02-16 WO disclosed
US-20060009371-A1 STABILIZED THICKENED HYDROGEN PEROXIDE CONTAINING COMPOSITIONS ARKEMA INC. 2006-01-12 US disclosed
US-20050226800-A1 Stabilization of alkaline hydrogen peroxide ARKEMA INC. 2005-10-13 US disclosed
EP-0183567-B1 PROCESS FOR PRODUCING POLYPHENYLENE ETHERS MITSUBISHI PETROCHEMICAL CO., LTD. (JP) 1989-03-29 EP disclosed
US-4617372-A MANGANESE SALT, OXINE DERIVATIVES, ALKANOLAMINE AND ALKALINE COMPOUND AS CATALYST MITSUBISHI PETROCHEMICAL CO, LTD. (JP) 1986-10-14 US disclosed
EP-0183567-A1 Process for producing polyphenylene ethers MITSUBISHI PETROCHEMICAL CO., LTD. (JP) 1986-06-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210307332-A1 POLYMER-STABILIZED AQUEOUS HYDROGEN PEROXIDE SOLUTIONS AND ASSOCIATED METHODS GPX4, PSPH, PHOSPHO1 HSP90AA1 1618/4885NPC1 4779/4885KMT2A 1815/4885
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression TERT, TERF2, RNGTT HSP90AA1 1080/4885NPC1 3227/4885KMT2A 280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.